
Opinion|Videos|November 16, 2023
Teclistamab plus Nirogacestat in RRMM: The MAJESTEC-2 Study
Drs Luciano Costa and Binod Dhakal discuss combining bispecific antibodies with gamma secretase inhibitors for the treatment of relapsed/refractory multiple myeloma, but trials show limited benefit and added toxicity; more promising are combinations with immunomodulators like isatuximab.
Advertisement
Episodes in this series

Advertisement
Related to this article

Ajai Chari, MD, discussed sequencing CAR T and bispecifics, fixed-duration therapy, emerging targets, and academic partnership in multiple myeloma.

At the 2026 Chemotherapy Foundation Symposium, Ajai Chari, MD, explained how disease pace and BCMA sequencing guide choosing CAR T or bispecifics.

Ralph V. Boccia, MD, FACP, details the home monitoring tools, prophylaxis, and grade-based approach his practice uses to manage CRS.

Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.

Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.

Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.

Ralph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.
Advertisement
Advertisement
Trending on CancerNetwork
1
Galinpepimut-S Improves Overall Survival in Phase 3 AML Maintenance Trial
2
FDA Approves Neladalkib in Advanced ALK+ Non–Small Cell Lung Cancer
3
FDA Grants Final Approval to Generic Binimetinib in BRAF-Mutant Melanoma, NSCLC
4
IDE849 Gains FDA Alignment on Registrational Trials in Neuroendocrine Carcinomas
5





